Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROMIS-II: Inhaled Colistimethate Sodium for Non-Cystic Fibrosis Bronchiectasis
NCT03460704Phase 3Terminated
- Sponsor
- Zambon
- Start
- Jan 2018
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 3 trial of colistimethate sodium in Non-cystic fibrosis bronchiectasis (NCFB), sponsored by Zambon. Started Jan 2018; status: terminated.
02
Drugs
colistimethate sodium
03
Conditions
Non-cystic fibrosis bronchiectasis (NCFB)
Beyond the preview
Go deeper on NCT03460704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03460704.